Company research
EBR Systems, Inc.
CIK 1347123Updated Sep 24, 2026
SecurityEBRCZ · OTC · equity
Name history
EBR Systems Inc · through Feb 10, 2011
EBRCZ price & chart
Loading TradingView…
OTC:EBRCZ on TradingView ↗About the company
Silicon Valley-based EBR Systems (ASX:EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 97,226,000Source | 73,559,494Source | 78,898,477Source |
| Property, Plant and Equipment, NetUSD | 5,477,000Source | 794,959Source | 1,088,771Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,794,000Source | 6,917,546Source | 14,578,752Source |
| Inventory, NetUSD | 13,789,000Source | 2,842,540Source | 0Source |
| Assets, CurrentUSD | 73,111,000Source | 64,466,383Source | 74,374,916Source |
| Operating Lease, Right-of-Use AssetUSD | 12,613,000Source | 929,243Source | 1,719,590Source |
| Other Assets, NoncurrentUSD | 546,000Source | 613,427Source | 589,646Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 71,638,000Source | 49,203,993Source | 47,842,025Source |
| Stockholders’ equity: | |||
| Common Stock, Value, IssuedUSD | 45,000Source | 37,108Source | 30,703Source |
| Additional Paid in CapitalUSD | 426,812,000Source | 376,902,576Source | 342,721,880Source |
| Retained Earnings (Accumulated Deficit)USD | -402,216,000Source | -353,457,680Source | -312,659,408Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 947,000Source | 873,497Source | 963,277Source |
| Stockholders' Equity Attributable to ParentUSD | 25,588,000Source | 24,355,501Source | 31,056,452Source |
| Liabilities and EquityUSD | 97,226,000Source | 73,559,494Source | 78,898,477Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 14,048,000Source | 8,327,994Source | 6,448,162Source |
| Operating Lease, Liability, CurrentUSD | 1,182,000Source | 522,525Source | 250,876Source |
| Accounts Payable, CurrentUSD | 7,049,000Source | 3,247,453Source | 1,856,134Source |
| Operating Lease, Liability, NoncurrentUSD | 16,520,000Source | 574,777Source | 1,670,230Source |
| Other Liabilities, NoncurrentUSD | 184,000Source | 37,617Source | 76,946Source |
| Additional Financial Items | |||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 54,200,000Source | 65,967,907Source | 73,440,580Source |
| Long-term DebtUSD | 41,800,000Source | 41,837,286Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -48,758,000Source | -40,798,272Source | -35,036,888Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation, Depletion and AmortizationUSD | 403,000Source | 587,485Source | 752,257Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 3,051,000Source | 1,742,279Source | 1,305,811Source |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in InventoriesUSD | 12,807,000Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | 2,240,000Source | 1,347,741Source | -86,347Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -53,192,000Source | -41,229,820Source | -32,697,514Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 7,836,000Source | 1,113,229Source | -8,640,990Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 3,683,000Source | 273,437Source | 354,054Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 46,829,000Source | 32,484,046Source | 40,465,924Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 1,480,000Source | -7,661,206Source | -877,586Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 8,398,000Source | 6,917,546Source | 14,578,752Source |
| Supplemental disclosure of cash flow information: | |||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 5,035,000Source | 5,412,170Source | 3,881,400Source |
| Income Taxes Paid, NetUSD | 2,000Source | 1,625Source | 775Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 7,000Source | -28,661Source | -5,006Source |
| Additional Financial Items | |||
| Accretion ExpenseUSD | 828,000Source | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 54,200,000Source | 65,967,907Source | 73,440,580Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -36,000Source | 9,979Source | -2,984Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | -38,000Source | — | — |
| General and Administrative ExpenseUSD | 22,637,000Source | 11,253,601Source | 7,402,921Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | 2,000Source | 1,535Source | 1,625Source |
| Investment Income, InterestUSD | 2,707,000Source | 3,180,984Source | 3,281,440Source |
| Marketable Securities, Unrealized Gain (Loss)USD | 47,000Source | -45,310Source | 171,135Source |
| Net Income (Loss) Attributable to ParentUSD | -48,758,000Source | -40,798,272Source | -35,036,888Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -48,758,000Source | -40,798,272Source | -35,036,888Source |
| Nonoperating Income (Expense)USD | -2,669,000Source | -2,477,709Source | -486,316Source |
| Operating ExpensesUSD | 46,577,000Source | 38,319,028Source | 34,548,947Source |
| Operating Lease, ExpenseUSD | 2,497,000Source | 613,345Source | 536,181Source |
| Other Nonoperating Income (Expense)USD | 304,000Source | 360,996Source | 718,959Source |
| Proceeds from Issuance of Common StockUSD | 48,828,000Source | 34,021,550Source | 21,615,076Source |
| Proceeds from Stock Options ExercisedUSD | 647,000Source | 486,033Source | 54,872Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total RevenueUSD | 1,617,000Source | — | — |
| Cost of Goods and Services Sold | — | — | — |
| Operating Income (Loss)USD | -46,087,000Source | -38,319,028Source | -34,548,947Source |
| Other Nonoperating Income (Expense)USD | 304,000Source | 360,996Source | 718,959Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -48,756,000Source | -40,796,737Source | -35,035,263Source |
| Income Tax Expense (Benefit)USD | 2,000Source | 1,535Source | 1,625Source |
| Net Income (Loss) Attributable to ParentUSD | -48,758,000Source | -40,798,272Source | -35,036,888Source |
| Earnings Per Share, BasicUSD per share | -0.12Source | -0.13Source | -0.12Source |
| Earnings Per Share, DilutedUSD per share | -0.12Source | -0.13Source | -0.12Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 417,327,276Source | 324,995,419Source | 288,875,373Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 417,327,276Source | 324,995,419Source | 288,875,373Source |
| Additional Financial Items | |||
| Current Income Tax Expense (Benefit)USD | 2,000Source | 1,535Source | 1,625Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 400,000Source | 587,485Source | 752,257Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -36,000Source | 9,979Source | -2,984Source |
| General and Administrative ExpenseUSD | 22,637,000Source | 11,253,601Source | 7,402,921Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source |
| Gross ProfitUSD | 490,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -47,281,000Source | -40,257,704Source | -34,789,313Source |
| Interest ExpenseUSD | 5,644,000Source | 6,029,668Source | 4,483,731Source |
| Interest Income (Expense), NetUSD | — | 3,180,984Source | 3,281,440Source |
| Interest Income, OperatingUSD | 2,707,000Source | — | — |
| Interest Income, OtherUSD | 1,879,000Source | — | — |
| Investment Income, InterestUSD | 2,707,000Source | 3,180,984Source | 3,281,440Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -48,758,000Source | -40,798,272Source | -35,036,888Source |
| Nonoperating Income (Expense)USD | -2,669,000Source | -2,477,709Source | -486,316Source |
| Operating ExpensesUSD | 46,577,000Source | 38,319,028Source | 34,548,947Source |
| Operating Lease, ExpenseUSD | 2,497,000Source | 613,345Source | 536,181Source |
| Research and Development ExpenseUSD | 23,940,000Source | 27,065,427Source | 27,146,026Source |
Filing attachments
ex99_1.htm · 8-K · 2026-08-24
EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 ASX ANNOUNCEMENT 21 August 2026 ──────────────────────────────────────── EBR announces transition of Chief Commercial Officer Santa Clara, California; 21 August 2026: EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), developer of the world’s only wireless cardiac pacing device for heart failure, today announced the impending departure of Erik Strandberg, Chief Commercial Officer, who will be leaving the Company in the c…
Read attachment ↗ex99_1.htm · 8-K · 2026-04-09
EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 ASX ANNOUNCEMENT 9 April 2026 ────────────────────────────────────── EBR Reports Strong Q1 2026 Growth in Commercial Cases Key Highlights Robust commercial momentum continued through Q1 2026 with case volumes more than doubling from Q4 2025 ─────────────────────────────────────────────────────────────────────────────── The WiSE® System was successfully implanted in 41 commercial patients during the quarter, bringing total i…
Read attachment ↗ex99_1.htm · 8-K · 2026-01-13
EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 ASX ANNOUNCEMENT 12 January 2026 ───────────────────────────────────────── EBR Announces Strong Q4 FY2025 Commercial and Clinical Progress Key Highlights Strong commercial momentum continued through Q4 2025 with case volumes doubling from Q3 2025 ─────────────────────────────────────────────────────────────────────────────────── The WiSE® System was successfully implanted in 18 commercial patients during the quarter, reachi…
Read attachment ↗ex99_1.htm · 8-K · 2025-04-15
EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 ASX ANNOUNCEMENT 15 April 2025 ─────────────────────────────────────── CMS Proposes Approval of NTAP Reimbursement Key Highlights: The Centers for Medicare & Medicaid Services (CMS) is proposing to approve the WiSE® CRT System for the New Technology Add-On Payment (NTAP) for FY 2026 CMS has recommended WiSE receive the maximum add-on payment of 65% of the device cost, which is in addition to the normal MS-DRG payment. In com…
Read attachment ↗ex99_1.htm · 8-K · 2025-04-14
EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 ASX ANNOUNCEMENT 14 April 2025 ─────────────────────────────────────── FDA Approval of WiSE ® CRT System Key highlights: EBR Systems has secured FDA approval for the WiSE CRT System—the world’s first and only leadless solution for left ventricular endocardial pacing. For the first time, clinicians can deliver cardiac resynchronization therapy without leads EBR will initially target a US$3.6 billion addressable market ac…
Read attachment ↗